stoxline Quote Chart Rank Option Currency Glossary
Aravive, Inc. (ARAV)
0.0401  -0.006 (-13.39%)    01-26 16:00
Open: 0.0435
High: 0.046
Volume: 4,040,076
Pre. Close: 0.0463
Low: 0.0401
Market Cap: 3(M)
Technical analysis
2024-03-08 4:50:18 PM
Short term     
Mid term     
Targets 6-month :  0.11 1-year :  0.15
Resists First :  0.09 Second :  0.12
Pivot price 0.04
Supports First :  0.03 Second :  0.03
MAs MA(5) :  0.04 MA(20) :  0.06
MA(100) :  0.12 MA(250) :  0.88
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  0.2 D(3) :  0.1
RSI RSI(14): 20.5
52-week High :  2.46 Low :  0.03
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ARAV ] has closed above bottom band by 33.6%. Bollinger Bands are 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.04 - 0.04 0.04 - 0.04
Low: 0.04 - 0.04 0.04 - 0.04
Close: 0.04 - 0.04 0.04 - 0.04
Company Description

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Headline News

Sun, 23 Jun 2024
Cantor Fitzgerald Reiterates Aravive (ARAV) Overweight Recommendation - MSN

Fri, 21 Jun 2024
Aravive (ARAV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Lifestyle UK

Fri, 19 Jan 2024
Houston biotech company Aravive to delist from Nasdaq, approves liquidation - Houston Business Journal

Thu, 18 Jan 2024
Nasdaq Jumps Over 100 Points; US Jobless Claims Fall To 187000 - Agrify (NASDAQ:AGFY) - Benzinga

Thu, 18 Jan 2024
Why Is Aravive (ARAV) Stock Down 52% Today? - InvestorPlace

Wed, 17 Jan 2024
Aravive, Inc. to Delist from The Nasdaq Stock Market - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 74 (M)
Shares Float 45 (M)
Held by Insiders 38.6 (%)
Held by Institutions 8.2 (%)
Shares Short 1,330 (K)
Shares Short P.Month 2,470 (K)
Stock Financials
EPS -0.76
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.01
Profit Margin 0 %
Operating Margin -323.5 %
Return on Assets (ttm) -134.1 %
Return on Equity (ttm) -476 %
Qtrly Rev. Growth -44.5 %
Gross Profit (p.s.) 0
Sales Per Share 0.09
EBITDA (p.s.) -0.8
Qtrly Earnings Growth 0 %
Operating Cash Flow -59 (M)
Levered Free Cash Flow -38 (M)
Stock Valuations
PE Ratio -0.06
PEG Ratio 0
Price to Book value 2
Price to Sales 0.42
Price to Cash Flow -0.05
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android